Report top-line results from the Phase 2 study of ACP-044
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Nov 2021
- Due
- 31 Mar 2022
- Delivered
- April 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Top-line results from the Phase 2 study of ACP-044 for the treatment of postoperative pain following bunionectomy surgery are expected in the first quarter of 2022.”
What we found
Evidence strength A What the grades mean
The company announced the top-line results for the ACP-044 Phase 2 study in April 2022, which occurred after the first quarter 2022 deadline.
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2022-05-05
“In April 2022, we announced top-line results from the ACP-044 study for the treatment of acute postoperative pain which did not meet its primary endpoint” ✓ confirmed on the page
Market reaction: the shares moved -10.4% against the S&P 500 over the three sessions around the disclosure (4 May 2022 to 9 May 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Phase 2 study of ACP-044 top-line results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ACAD-002571 · Corrections policy